45 related articles for article (PubMed ID: 21546157)
1. Annexin V-targeted enzyme prodrug therapy using cytosine deaminase in combination with 5-fluorocytosine.
Van Rite BD; Harrison RG
Cancer Lett; 2011 Aug; 307(1):53-61. PubMed ID: 21546157
[TBL] [Abstract][Full Text] [Related]
2. Purine nucleoside phosphorylase targeted by annexin v to breast cancer vasculature for enzyme prodrug therapy.
Krais JJ; De Crescenzo O; Harrison RG
PLoS One; 2013; 8(10):e76403. PubMed ID: 24098491
[TBL] [Abstract][Full Text] [Related]
3. Influence of the prodrugs 5-fluorocytosine and CPT-11 on ovarian cancer cells using genetically engineered stem cells: tumor-tropic potential and inhibition of ovarian cancer cell growth.
Kim KY; Kim SU; Leung PC; Jeung EB; Choi KC
Cancer Sci; 2010 Apr; 101(4):955-62. PubMed ID: 20704576
[TBL] [Abstract][Full Text] [Related]
4. Bacterial cytosine deaminase mutants created by molecular engineering show improved 5-fluorocytosine-mediated cell killing in vitro and in vivo.
Fuchita M; Ardiani A; Zhao L; Serve K; Stoddard BL; Black ME
Cancer Res; 2009 Jun; 69(11):4791-9. PubMed ID: 19487291
[TBL] [Abstract][Full Text] [Related]
5. Nanoplex delivery of siRNA and prodrug enzyme for multimodality image-guided molecular pathway targeted cancer therapy.
Li C; Penet MF; Wildes F; Takagi T; Chen Z; Winnard PT; Artemov D; Bhujwalla ZM
ACS Nano; 2010 Nov; 4(11):6707-16. PubMed ID: 20958072
[TBL] [Abstract][Full Text] [Related]
6. Enzyme Prodrug Therapy with Photo-Cross-Linkable Anti-EGFR Affibodies Conjugated to Upconverting Nanoparticles.
Roy S; Curry SD; Corbella Bagot C; Mueller EN; Mansouri AM; Park W; Cha JN; Goodwin AP
ACS Nano; 2022 Oct; 16(10):15873-15883. PubMed ID: 36129781
[TBL] [Abstract][Full Text] [Related]
7. Escherichia coli cytosine deaminase: Structural and biotechnological aspects.
Vosough P; Vafadar A; Naderi S; Alashti SK; Karimi S; Irajie C; Savardashtaki A; Taghizadeh S
Biotechnol Appl Biochem; 2024 Feb; 71(1):5-16. PubMed ID: 37743549
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic Efficacy of Prodrug Activator Gene Therapy Using Retroviral Replicating Vectors for Human Ovarian Cancer.
Isoda L; Sonoda-Fukuda E; Fujino H; Takarada T; Hasegawa K; Kasahara N; Kubo S
Anticancer Res; 2023 Dec; 43(12):5311-5317. PubMed ID: 38030176
[TBL] [Abstract][Full Text] [Related]
9. Exploring Product Release from Yeast Cytosine Deaminase with Metadynamics.
Croney KA; McCarty J
J Phys Chem B; 2024 Apr; 128(13):3102-3112. PubMed ID: 38516924
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of gene therapy-delivered cytosine deaminase is determined by enzymatic activity but not expression.
Dubois L; Dresselaers T; Landuyt W; Paesmans K; Mengesha A; Wouters BG; Van Hecke P; Theys J; Lambin P
Br J Cancer; 2007 Mar; 96(5):758-61. PubMed ID: 17311022
[TBL] [Abstract][Full Text] [Related]
11. Anticancer effects of the engineered stem cells transduced with therapeutic genes via a selective tumor tropism caused by vascular endothelial growth factor toward HeLa cervical cancer cells.
Kim HS; Yi BR; Hwang KA; Kim SU; Choi KC
Mol Cells; 2013 Oct; 36(4):347-54. PubMed ID: 24008363
[TBL] [Abstract][Full Text] [Related]
12. Genetically engineered neural stem cells expressing cytosine deaminase and interferon-beta enhanced T cell-mediated antitumor immunity against gastric cancer in a humanized mouse model.
Choi Y; Lee HK; Ahn D; Nam MW; Go RE; Choi KC
Life Sci; 2023 Sep; 328():121866. PubMed ID: 37331506
[TBL] [Abstract][Full Text] [Related]
13. Asymmetrical dose responses shape the evolutionary trade-off between antifungal resistance and nutrient use.
Després PC; Cisneros AF; Alexander EMM; Sonigara R; Gagné-Thivierge C; Dubé AK; Landry CR
Nat Ecol Evol; 2022 Oct; 6(10):1501-1515. PubMed ID: 36050399
[TBL] [Abstract][Full Text] [Related]
14. Bi-Functional Radiotheranostics of
Huang YS; Hsu WC; Lin CH; Lo SN; Cheng CN; Lin MS; Lee TW; Chang CH; Lan KL
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33672989
[TBL] [Abstract][Full Text] [Related]
15. The bifunctional SDF-1-AnxA5 fusion protein protects cardiac function after myocardial infarction.
Huang FY; Xia TL; Li JL; Li CM; Zhao ZG; Lei WH; Chen L; Liao YB; Xiao D; Peng Y; Wang YB; Liu XJ; Chen M
J Cell Mol Med; 2019 Nov; 23(11):7673-7684. PubMed ID: 31468674
[TBL] [Abstract][Full Text] [Related]
16. Domain IV of Annexin A5 Is Critical for Binding Calcium and Guarantees Its Maximum Binding to the Phosphatidylserine Membrane.
Wang J; Liu J; Cao Y; Hu M; Hua Z
Molecules; 2017 Dec; 22(12):. PubMed ID: 29257055
[No Abstract] [Full Text] [Related]
17. Annexin-directed β-glucuronidase for the targeted treatment of solid tumors.
Guillen KP; Ruben EA; Virani N; Harrison RG
Protein Eng Des Sel; 2017 Feb; 30(2):85-94. PubMed ID: 27986920
[TBL] [Abstract][Full Text] [Related]
18. Targeted antitumor prodrug therapy using CNGRC-yCD fusion protein in combination with 5-fluorocytosine.
Li JJ; Chang SF; Liau II; Chan PC; Liu RS; Yen SH; Wang HE; Chang CA
J Biomed Sci; 2016 Jan; 23():15. PubMed ID: 26801910
[TBL] [Abstract][Full Text] [Related]
19. Targeted enzyme prodrug therapy for metastatic prostate cancer - a comparative study of L-methioninase, purine nucleoside phosphorylase, and cytosine deaminase.
Guillen KP; Kurkjian C; Harrison RG
J Biomed Sci; 2014 Jul; 21(1):65. PubMed ID: 25047949
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
